Health and Healthcare
Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)
Published:
Last Updated:
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.
The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.
The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
